Dr. Luke Laffin and I discuss: Efficacy Of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension On A Standardized Antihypertensive Medication Regimen March 29, 2025 2025 | ACC | Cardiology | Slides | Trial | Video Disclosures: TBD LukeLaffinADVANCE HTN – LBCT Presentation – 25MARCH2025Download Article Navigation Dr. Hyo-Soo Kim and I discussed the HOST-BR trial on optimal DAPT duration and thrombosis-bleeding balance in ACS patients. 3-month DAPT reduced thrombosis vs. 1-month in high bleeding risk, and reduced bleeding vs. 12-month in low-risk patients Dr. Antonius Buescher and I discuss: Development And External Validation Of A Deep Learning Electrocardiogram Model For Risk Stratification Of Coronary Revascularization Need In The Emergency Department
